• Home
  • EMCrit
  • PulmCrit
  • IBCC
  • ODR
  • About
    • About EMCrit
    • PulmCrit – The Full Story
    • EMCrit FAQ
    • Subscribe to the Newsletter
  • Contact
  • Join
    • Why Should I Become a Member?
    • Questions Before Joining (FAQ)
    • Join Now!

Internet Book of Critical Care (IBCC)

Online Medical Education on Emergency Department (ED) Critical Care, Trauma, and Resuscitation

  • ToC
  • About the IBCC
  • Tweet Us
  • IBCC Podcast
You are here: Home / IBCC / Torsade de pointes


Torsade de pointes

November 22, 2021 by Josh Farkas

CONTENTS

  • Rapid Reference 🚀
  • Diagnosis of torsade
  • Treatment
    • #1: Breaking active polymorphic VT
    • #2: Basic treatment to stop torsade recurrence
    • #3: Management of refractory torsade storm
  • Podcast
  • Questions & discussion
  • Pitfalls

rapid reference

(back to contents)



Diagnosis of torsade

(back to contents)


getting some definitions straight

  • Polymorphic ventricular tachycardia
    • Defined as ventricular tachycardia with varying QRS amplitude.
    • This is commonly referred to as torsade de pointes, but it's actually not the same thing. Polymorphic ventricular tachycardia may be caused by several etiologies (e.g., congenital QT prolongation, acquired QT prolongation, ischemia, Takotsubo's cardiomyopathy).
  • Torsade de Pointes
    • Torsade is defined as the combination of polymorphic ventricular tachycardia plus a prolonged QT-interval.
    • Torsade can be caused by either congenital long-QT syndrome or acquired long-QT syndrome (due to electrolyte abnormalities and/or medications). The vast majority of torsade results from acquired long-QT syndrome, which is the focus of this chapter.

how to measure QT & QTc interval

  • The EKG computer will often get this right, but it cannot be relied upon.
  • QT may vary between leads. The lead with the longest easily measurable QT interval should be used.
  • If there is a U-wave, the QT interval should be determined as the intersection of the T-wave maximum slope with the isoelectric line (figure above).
  • The QTc may be determined using a calculator (e.g. MDCalc).
    • QTc >~475 ms is statistically elevated (above the 99th percentile).
    • Torsade is unusual unless QTc is >500 ms.(26183037)
  • Bundle branch blocks will prolong the QT without increasing the risk of torsade.(20142454) Interpretation of QT intervals here is murky; consider comparing to prior EKGs.

clinical presentations

  • Depending on the length of the episode and whether torsade degenerates into ventricular fibrillation, clinical presentations include:
    • Syncope or presyncope.
    • “Seizure” episode(s).
    • Cardiac arrest.
  • Telemetry monitoring during an episode makes the diagnosis more straightforward.

EKG differential diagnosis: things that masquerade as torsade

  • Severe hyperkalemia with “sine wave” pattern.
  • Coarse ventricular fibrillation.
  • Atrial fibrillation with Wolf Parkinson White (varying morphology may create polymorphic appearance).
  • Polymorphic ventricular tachycardia with normal QT interval (may be caused by acute myocardial ischemia, Takotsubo cardiomyopathy, or such genetic conditions as catecholaminergic VT).

Tx #1: breaking active polymorphic VT

(back to contents)


unstable: immediate defibrillation

  • Patients with unstable polymorphic VT need immediate defibrillation.
  • The defibrillator will often be unable to lock onto any QRS complexes, so you generally need to perform an unsynchronized defibrillation.
  • Technically the appropriate amount of energy is 200J biphasic. However, it might also be reasonable to use more energy particularly in a larger patient (with the rationale that unsuccessful defibrillation could be very dangerous, potentially pushing the patient into ventricular fibrillation).

“stable polymorphic VT”

  • Polymorphic VT is never truly stable. This is a short-lived transitional state which usually flips back into sinus rhythm, or less commonly degenerates into ventricular fibrillation. Even if the patient looks OK, they're not really stable: attach pads and don't leave the room.
  • Given the risk of degeneration into VF, urgent defibrillation is reasonable if the patient shows any hint of instability.
  • Intravenous magnesium is a reasonable treatment, but a practitioner should be in the patient's room with a defibrillator ready to shock the patient.
    • Give 2 grams (8 mM) IV magnesium sulfate over ~10 minutes, repeat if no response. If the patient remains stable and the rhythm persists, repeat an EKG and consider the possibility of an alternative diagnosis.
    • Note that most treatments associated with torsade are used for the prevention of VT, not breaking an episode of VT. Thus treatments such as isoproterenol or pacing have no role here.

Tx #2: Basic tx to prevent recurrent torsade

(back to contents)


If the EKG shows a prolonged QT-interval and a prior EKG shows a normal QT-interval, then the patient is diagnosed with torsade due to acquired QT prolongation. If you simply break torsade but do nothing else, it is likely to recur. The following therapies will prevent recurrence:

(#1/3) magnesium is 1st line therapy

  • Patients with torsade should receive magnesium, even if they have a normal magnesium level.
  • Four grams magnesium sulfate IV (16 mM) is a reasonable place to start. Unfortunately, if you stop after four grams then the magnesium level will fall over several hours and torsade may recur.(29169799)
  • Additional magnesium should be provided based on the patient's renal function:
    • (a) If GFR > 30 ml/min, a magnesium infusion is useful (see protocol below).
    • (b) If GFR < 30 ml/min, cycle magnesium levels and bolus intermittently to target a magnesium level of 3.5-5 mg/dL (1.5-2 mM).
  • Magnesium has a very wide safety margin. A protocoled magnesium infusion may seem aggressive, but overall this is far safer than the risk of recurrent cardiac arrest.
  • Below is a magnesium protocol (one version in American units, one in SI units).(7587256, 18320707) This will work best if pasted directly into the patient's chart so that everyone is literally on the same page.🌊

(#2/3) treat any other precipitating factors:

  • Hypokalemia, should be treated aggressively, targeting a high-normal potassium level (>4.5 mEq/L).(29084733)
  • Hypocalcemia may promote torsade and should be treated if present.📖
  • Hypothermia should be aggressively reversed.📖

(#3/3) cessation of all QT-prolonging medications

  • The medication list should be carefully reviewed for any medications which may prolong QT interval. Patients are often on several QT-prolonging medications, all of which should be stopped if possible.
  • Evidence regarding which drugs cause torsade is extremely murky. In some cases it seems that drugs have been incorrectly maligned (e.g. azithromycin, olanzapine). One complicating factor is that there isn't a simple relationship between QT prolongation and torsade (some drugs such as amiodarone increase the QT, without causing much torsade).

more common medications linked to torsade (26183037, 20142454, 29084733)

  • Antiarrhythmics:
    • Class IA: Quinidine, disopyramide, procainamide.
    • Class IC: Flecainide.
    • Class III: Dofetilide, ibutilide, sotalol, dronedarone.
  • Psychotropic:
    • Haloperidol, droperidol, chlorpromazine, pimozide.
    • Citalopram, escitalopram.
    • Tricyclic antidepressants.
  • Antibiotics:
    • Clarithromycin, erythromycin.
    • Fluoroquinolones.
    • Fluconazole, itraconazole, voriconazole, posaconazole.
    • Pentamidine.
  • Other:
    • Methadone.
    • Cocaine, loperamide (when abused in massive doses).
    • Ondansetron (primarily when pushed rapidly).
    • Propofol.
    • Arsenic trioxide, sunitinib, vandetanib.

Tx #3: Refractory torsade storm

(back to contents)


Occasional patients will have recurrent episodes of torsade (“Torsade storm”). Each individual episode may be treated with magnesium or defibrillation, if needed (Treatment step #1 above). However, additional therapies are required to stop recurrence and end the storm.

re-load magnesium if needed

  • Recurrent torsade may reflects inadequate magnesium dosing (e.g., patient is bolused with 2-4 grams, without an infusion). The first step when managing recurrent torsade is therefore to ensure that the patient has truly received an adequate dose of magnesium.
  • If the patient was bolused with magnesium a few hours ago without an infusion, re-load with 2-4 grams IV immediately (8-16 mM).
  • If the patient is a candidate for magnesium infusion (GFR >30 ml/hr), this should be started.
  • If the patient has renal failure and has already received 4-6 grams of magnesium (16-24 mM), then check magnesium levels and ensure that a high level is achieved. Note that a therapeutic level for torsade is roughly 3.5-5 mg/dL (1.5-2 mM) – not a “normal” level.
  • More on magnesium above.📖

treat any other precipitating factors

  • Hypokalemia, should be treated aggressively, targeting a high-normal potassium level (>4.5 mEq/L).(29084733)
  • Hypocalcemia may promote torsade and should be treated if present.📖
  • Hypothermia should be aggressively reversed.📖

speed up the heart

  • Speeding up the heart rate will generally decrease the QT interval and reduce the risk of acquired torsade. However, this probably doesn't work in Type-I congenital long-QT syndrome, which is not a pause-dependent arrhythmia. 📄 (34039680)
  • The usefulness of chronotropy depends on the patient's baseline heart rate.
    • Chronotropy is most beneficial for patients starting out with bradycardia.
    • If the patient is already significantly tachycardic, chronotropy is unlikely to provide benefit. The usual target heart rate is 100-110 b/m, but occasionally heart rates up to 140 b/m may be needed.(26183037) There's no high-quality data on this.
  • Medical chronotropy is generally the easiest & fastest way to stabilize the patient. The ideal chronotrope depends on the patient's hemodynamics and baseline blood pressure.
    • Baseline severe hypotension: epinephrine infusion.
    • Baseline normotension or mild hypotension: dobutamine or isoproterenol infusion.
    • ⚠️ Caution: If chronotropic therapy causes lots of premature ventricular complexes, this may be counterproductive (since premature ventricular complexes can trigger torsade).(31114687) In this situation, consider transvenous pacing and/or lidocaine.
    • ⚠️ Caution: Beta-adrenergic agonists are contraindicated in patients with congenital long-QT syndrome.
  • Electrical chronotropy may be used if medical chronotropy fails or is contraindicated:
    • Transcutaneous pacing may work, but this is painful for conscious patients.
    • Transvenous pacing is more comfortable, but this is more invasive and takes a bit longer to achieve.
    • Patients with a pacemaker may have the device rate increased.

lidocaine 💊

  • Lidocaine is the preferred antiarrhythmic drug for torsade, although there isn't a ton of evidence supporting its use.
    • Do not use amiodarone, procainamide, beta-blockers, or most other antiarrhythmics. Most of these will stretch out the QT interval even further! Beta-blockers will slow down the heart rate, increasing the risk of torsade (although beta-blockers may be beneficial in some patients with congenital long-QT syndrome).📄 (34039680)
  • Start with a loading dose of 1-1.5 mg/kg lidocaine followed by a 1 mg/min infusion. For recurrent arrhythmias, re-load with another 1 mg/kg bolus and increase the maintenance infusion to 2-3 mg/min.

consider an alternative diagnosis

  • Acquired torsade is generally fairly easy to control with a combination of high-dose magnesium, heart rate augmentation, and occasionally some lidocaine. Failure to respond to these interventions suggests an alternative diagnosis (e.g. polymorphic VT due to ischemia, catecholaminergic ventricular tachycardia, or congenital long-QT syndrome).

podcast

(back to contents)


Follow us on iTunes

The Podcast Episode

http://traffic.libsyn.com/ibccpodcast/Torsades_Final.mp3

Want to Download the Episode?
Right Click Here and Choose Save-As


questions & discussion

(back to contents)


To keep this page small and fast, questions & discussion about this post can be found on another page here.

  • Under-dosing magnesium (e.g. giving two-four grams magnesium and walking away). This will often cause recurrence of ventricular tachycardia in a few hours after the serum magnesium levels fall.
  • Leaving patients on QT-prolonging meds (make sure to scour the medication list for any problematic drugs).
  • Don't give amiodarone or other QT-prolonging antiarrhythmics (e.g. procainamide). These may actually aggravate the situation.
  • Recognize that polymorphic VT with a normal QT interval isn't torsade, this requires an entirely different treatment strategy.

Guide to emoji hyperlinks 🔗

  • 🧮 = Link to online calculator.
  • 💊 = Link to Medscape monograph about a drug.
  • 💉 = Link to IBCC section about a drug.
  • 📖 = Link to IBCC section covering that topic.
  • 🌊 = Link to FOAMed site with related information.
  • 📄 = Link to open-access journal article.
  • 🎥 = Link to supplemental media.

Going further

  • New approach to Torsade (PulmCrit) & Prior post on Mg infusions
  • QT-interval and Torsade & polymorphic VT (Ed Burns, LITFL)
  • Podcast on torsade by Rob Orman and Joe Bellezzo (ERCast). This is a pretty epic episode and well worth listening to. I wholeheartedly agree with Joe Bellezzo regarding the need to do something pro-active to prevent recurrent torsade, but would suggest that a magnesium infusion can be used instead of temporary transvenous pacing.
  • Polymorphic VT (Steve Smith's ECG blog)
  • Torsade de Pointes (Justin Morganstern, First 10 in EM)
  • EKG pointers: Is it Torsade de Pointes? (emDocs)

References

  • 07587256 Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med. 1995 Nov;23(11):1816-24. doi: 10.1097/00003246-199511000-00005 [PubMed]
  • 18320707 Sleeswijk ME, Tulleken JE, Van Noord T, Meertens JH, Ligtenberg JJ, Zijlstra JG. Efficacy of magnesium-amiodarone step-up scheme in critically ill patients with new-onset atrial fibrillation: a prospective observational study. J Intensive Care Med. 2008 Jan-Feb;23(1):61-6. doi: 10.1177/0885066607310181 [PubMed]
  • 20142454 Drew BJ, Ackerman MJ, Funk M, et al.; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010 Mar 2;121(8):1047-60. doi: 10.1161/CIRCULATIONAHA.109.192704 [PubMed]
  • 26183037 Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol. 2016 Mar;81(3):420-7. doi: 10.1111/bcp.12726 [PubMed]
  • 29084733 Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e210-e271. doi: 10.1161/CIR.0000000000000548 [PubMed]
  • 29169799 Biesenbach P, Mårtensson J, Lucchetta L, Bangia R, Fairley J, Jansen I, Matalanis G, Bellomo R. Pharmacokinetics of Magnesium Bolus Therapy in Cardiothoracic Surgery. J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1289-1294. doi: 10.1053/j.jvca.2017.08.049 [PubMed]
  • 31114687 El-Sherif N, Turitto G, Boutjdir M. Acquired Long QT Syndrome and Electrophysiology of Torsade de Pointes. Arrhythm Electrophysiol Rev. 2019 May;8(2):122-130. doi: 10.15420/aer.2019.8.3 [PubMed]
  • 33495078 Niimi N, Yuki K, Zaleski K. Long QT Syndrome and Perioperative Torsades de Pointes: What the Anesthesiologist Should Know. J Cardiothorac Vasc Anesth. 2020 Dec 13:S1053-0770(20)31356-2. doi: 10.1053/j.jvca.2020.12.011 [PubMed]
  • 34039680 Wilde AAM, Amin AS, Postema PG. Diagnosis, management and therapeutic strategies for congenital long QT syndrome. Heart. 2021 May 26:heartjnl-2020-318259. doi: 10.1136/heartjnl-2020-318259 [PubMed] 📄
  • 34151491 Lankaputhra M, Voskoboinik A. Congenital Long QT Syndrome: A Clinician's Guide. Intern Med J. 2021 Jun 20. doi: 10.1111/imj.15437 [PubMed]

The Internet Book of Critical Care is an online textbook written by Josh Farkas (@PulmCrit), an associate professor of Pulmonary and Critical Care Medicine at the University of Vermont.


Who We Are

We are the EMCrit Project, a team of independent medical bloggers and podcasters joined together by our common love of cutting-edge care, iconoclastic ramblings, and FOAM.

Resus Leadership Academy

Subscribe by Email

EMCrit is a trademark of Metasin LLC. Copyright 2009-. This site represents our opinions only. See our full disclaimer, our privacy policy, commenting policy and here for credits and attribution.

Insert/edit link

Enter the destination URL

Or link to existing content

    No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.